WO2007090721A1 - Compositions pharmaceutiques contenant des mélanges de polymères et d'agents actifs peu solubles dans l'eau - Google Patents

Compositions pharmaceutiques contenant des mélanges de polymères et d'agents actifs peu solubles dans l'eau Download PDF

Info

Publication number
WO2007090721A1
WO2007090721A1 PCT/EP2007/050465 EP2007050465W WO2007090721A1 WO 2007090721 A1 WO2007090721 A1 WO 2007090721A1 EP 2007050465 W EP2007050465 W EP 2007050465W WO 2007090721 A1 WO2007090721 A1 WO 2007090721A1
Authority
WO
WIPO (PCT)
Prior art keywords
water
pharmaceutical composition
meth
composition according
active ingredient
Prior art date
Application number
PCT/EP2007/050465
Other languages
German (de)
English (en)
Inventor
Christian Meier
Kathrin Nollenberger
Andreas Gryczke
Hans-Ulrich Petereit
Jennifer Dressman
Original Assignee
Evonik Röhm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Röhm Gmbh filed Critical Evonik Röhm Gmbh
Priority to PL07703962T priority Critical patent/PL1978936T3/pl
Priority to US12/159,538 priority patent/US20090011007A1/en
Priority to EP07703962.6A priority patent/EP1978936B1/fr
Priority to BRPI0707465A priority patent/BRPI0707465B8/pt
Priority to ES07703962T priority patent/ES2427724T3/es
Priority to KR1020087019038A priority patent/KR101387249B1/ko
Priority to CA2641351A priority patent/CA2641351C/fr
Priority to SI200731314T priority patent/SI1978936T1/sl
Priority to JP2008552772A priority patent/JP2009525300A/ja
Publication of WO2007090721A1 publication Critical patent/WO2007090721A1/fr
Priority to IL191604A priority patent/IL191604A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Definitions

  • compositions containing mixtures of polymers and poorly water-soluble active ingredients are provided.
  • the invention relates to various pharmaceutical compositions containing mixtures of polymers and poorly water-soluble active ingredients
  • EP 0 058 765 B1 describes gastric juice-soluble, swellable coating compositions and their use in a process for coating dosage forms. These are, in particular, water-soluble (meth) acrylate copolymers which are composed, in whole or in part, of alkyl acrylates and / or alkyl methacrylates having a tertiary amino group in the alkyl radical.
  • US Pat. No. 6,391,338 describes the solubility improvement or increase in the bioavailability of substantially water-insoluble active compounds, such as, for example, B. ibuprofen, itraconazole and nifedipine by means of flash flow or extrusion of the active ingredients and polymers of the type EUDRAGIT ® E.
  • active ingredients can go into an energetically higher state (solid dispersion) and then released in the form of nanoparticles in a dissolved state become.
  • US Pat. No. 6,319,520 describes controlled-release pharmaceutical compositions consisting of thermally formable mixtures of at least one active substance and one or more pH-independent polymers from the group of polymethacrylates.
  • the preparation of the pharmaceutical compositions can be carried out by means of injection molding, co-injection, extrusion or coextrusion.
  • preferred (Meth) acrylate copolymers are EUDRAGIT® RL and RS, which may optionally also be used together with S100 EUDRAGIT ® E or EUDRAGIT® L100, L100-55 and / or.
  • the active ingredients Benfluorex hydrochloride, Rilmetidin dihydrogen, Fenspirid hydrochloride with EUDRAGIT® RL, RS and their mixtures are processed by extrusion or injection molding.
  • WO 01/39751 A1 describes a process for the production of moldings by means of injection molding.
  • the process steps comprise a) melting a (meth) acrylate copolymer, which consists of 30 to 80 wt .-% of radically polymerized C1 to C4 alkyl esters of acrylic or methacrylic acid and 70 to 20 wt .-% (meth) acrylate Monomers having a tertiary ammonium group in the alkyl radical, wherein the (meth) acrylate copolymer is present in admixture with 1 to 70 wt .-% of a plasticizer and a desiccant in the ratio 1: 1 to 1: 20, wherein at least 1 wt.
  • % Softener is contained, and 0.05 to 5 wt .-% of a release agent are contained and in addition further conventional additives or excipients and optionally a pharmaceutical active ingredient may be included in the mixture and the mixture before melting with a content of low-boiling constituents a vapor pressure of at least 1, having 9 bar at 120 0 C of more than 0.5 wt .-%, b) degassing the mixture in the thermoplastic state at temperatures of at least 120 0 C, wodurc h the content of the low-boiling constituents with a vapor pressure of at least 1.9 bar at 120 ° C.
  • the (meth) acrylate copolymer which may preferably be an EUDRAGIT® E, may be present for controlling the release of active ingredient in a mixture with other polymers.
  • the proportion of further polymers should not be more than 20% by weight, preferably not more than 10% by weight, in particular 0-5% by weight.
  • EUDRAGIT® NE 30 D, EUDRAGIT® RS and EUDRAGIT® RL As further polymers for mixtures, i.a. EUDRAGIT® NE 30 D, EUDRAGIT® RS and EUDRAGIT® RL.
  • the method can be applied to any active ingredients, i.a. is also called ranitidine.
  • WO 01/43935 A2 describes a process for the production of moldings by means of injection molding with the process steps
  • a (meth) acrylate copolymer consisting of 40 to 100 wt .-% radically polymerized C 1 to C 4 alkyl esters of acrylic or methacrylic acid and 0 to 60 wt .-% (meth) acrylate monomers with an anionic group in the alkyl radical
  • the mixture may contain 0 to 20% by weight of another polymer or copolymer g). To control the release of active ingredient, it may be advantageous in individual cases to mix in other polymers. However, the proportion of further polymers in the mixture is not more than 20% by weight, preferably not more than 10% by weight, in particular 0-5% by weight, based on the (meth) acrylate copolymer.
  • Such further polymers include polyvinylpyrrolidones, polyvinyl alcohols, cationic (meth) acrylate copolymers of methyl methacrylate and / or ethyl acrylate and 2-dimethylaminoethyl methacrylate (EUDRAGIT ® E100), carboxymethylcellulose salts, hydroxypropylcellulose (HPMC), neutral (meth) acrylate copolymers composed of Methyl methacrylate and ethyl acrylate (dry matter from EUDRAGIT ® NE 30 D), copolymers of methyl methacrylate and butyl methacrylate (PLASTOI D ® B) or (meth) acrylate Copolymers having quaternary ammonium groups, trimethylammoniumethyl methacrylate chloride, as the monomer containing (EUDRAGIT ® RL, EUDRAGIT ® RS).
  • EUDRAGIT ® E100 cationic (meth) acrylate
  • WO 2004/019918 describes a process for producing a granulate or powder, suitable as a coating and binding agent for oral or dermal dosage forms, for cosmetics or dietary supplements, consisting essentially of (a) a copolymer consisting of radically polymerized C 1 to C 4 Esters of acrylic or methacrylic acid and further (meth) acrylate monomers having functional tertiary amino groups, (b) 3 to 25 wt .-%, based on (a), of an emulsifier having an HLB value of at least 14, (c ) 5 to 50 wt .-%, based on (a), a C12 to C18 monocarboxylic acid or a C-12 to cis-hydroxyl compound, wherein the components (a), (b) and (c) optionally with the addition a pharmaceutically active substance and / or further conventional additives are mixed or mixed with one another simultaneously or successively, melted in a heatable mixer, mixed, the melt is cooled and comminuted to
  • the granulates and powders obtained according to the method are particularly suitable for the formulation of moisture-sensitive pharmaceutical active substances such as acetylsalicylic acid, carbenoxolone, cefalotin, epinefrin, imipramine, potassium iodide, ketoprofen, levodopa, nitrazepam, nitroprusside, oxitetracycline HCl, promethazine, omeprazole or other benzimidazole derivatives, ranitidine or streptomycin.
  • moisture-sensitive pharmaceutical active substances such as acetylsalicylic acid, carbenoxolone, cefalotin, epinefrin, imipramine, potassium iodide, ketoprofen, levodopa, nitrazepam, nitroprusside, oxitetracycline HCl, promethazine, omeprazole or other benzimidazole derivatives, ranitidine or str
  • US Pat. No. 6,391,338 describes the solubility improvement or increase in the bioavailability of substantially water-insoluble active compounds, such as, for example, B. ibuprofen, itraconazole and nifedipine by means of flash flow or extrusion of the active ingredients and polymers of the type EUDRAGIT ® E.
  • active ingredients can go into an energetically higher state (solid dispersion) and then released in the form of nanoparticles in a dissolved state become. It is a scientifically remarkable approach, which in many cases leads to good results.
  • compositions formulated according to US Pat. No. 6,391,338 typically have the property of containing an active ingredient having a solubility in demineralized water of 3.3 g / L or less after dissolving an EUDRAGIT® E-matrix at acidic pH in dissolved form initially at least twice the solubility value of the drug in demineralised water.
  • the inventors have found that this effect persists only for a relatively short period of time. After the initial increase in the concentration of the measurably dissolved active ingredient, it falls below the limit of twice the solubility value of the active ingredient in demineralized water.
  • the measurement of the dissolved active ingredient can, depending on the type of active ingredient or type of active, z. B. by means of chromatographic or spectrometric methods, for. As UV measurement or HPLC, or be followed by other methods.
  • WO 01/39751 A1 describes a process for the production of moldings by means of injection molding.
  • the object is to be solved to provide (meth) acrylate copolymers with tertiary amino groups in a processable by injection molding, so that corresponding moldings are obtained in pharmaceutical grade.
  • (meth) acrylate copolymers with tertiary amino groups alone, it is also possible to process mixtures with EUDRAGIT® NE, EUDRAGIT® RS or RL. Examples of such mixtures alone or in combination with active ingredients are not included.
  • a person skilled in the art does not receive any indications from WO 01/39751 A1 to solve the abovementioned problem of effecting a prolonged improvement in the solubility of active substances which are sparingly soluble in water.
  • WO 01/43935 A2 describes a process for the production of moldings by means of injection molding.
  • the task should be solved, To provide (meth) acrylate copolymers with anionic groups in an injection-processable form, so that corresponding moldings obtained in pharmaceutical grade.
  • (meth) acrylate copolymers with anionic groups alone, it is also possible to process mixtures with EUDRAGIT® NE, EUDRAGIT® RS or RL. Examples of such mixtures alone or in combination with active ingredients are not included.
  • a person skilled in the art does not receive any indications from WO 01/43935 A2 for the solution of the abovementioned problem of effecting a prolonged improvement in the solubility of active substances which are sparingly soluble in water.
  • a pharmaceutical formulation should be provided for poorly water-soluble drugs in which an increased solubility and associated bioavailability of the drug in a gastric juice-like environment, pH 1, 2, is achieved and over a period of at least 120 minutes remains completely or at least partially stable.
  • the enteric-like test environment is the high requirement, so it can be assumed that the state of increased solubility, if it can be stably achieved in vitro at pH 1, 2 after 120 min, also in vivo after transition into the Bowel section at the prevailing higher pH levels no longer significantly adversely affected.
  • a pharmaceutical composition comprising a mixture of at least one cationic, water-soluble (meth) acrylate copolymer, at least one water-insoluble polymer and at least one active agent having a solubility in demineralized water of 3.3 g / l or less, characterized in that
  • the water-insoluble polymer and the active ingredient are present in a ratio of at most 3.5 to 1 parts by weight, and the pharmaceutical composition has the property of releasing the active substance contained in a buffered on pH 1, 2 medium in dissolved form in a concentration that after 2 Hours at pH 1, 2 is at least sixteen times the solubility value of the active ingredient alone at pH 1.2.
  • the invention further relates to two alternative processes for the preparation of the pharmaceutical compositions according to the invention.
  • the invention further relates to a process for the preparation of a dosage form comprising the pharmaceutical composition according to the invention and the dosage form resulting therefrom.
  • the invention further relates to the use of the pharmaceutical compositions according to the invention for the preparation of a dosage form.
  • the invention relates to a pharmaceutical composition, preferably in the form of a powder, comprising a mixture of at least one cationic, water-soluble (meth) acrylate copolymer, at least one water-insoluble polymer and at least one active substance having a solubility in demineralized water of 3.3 g / l or less .
  • the water-insoluble polymer and the active ingredient are present in a ratio of at most 3.5 to 1 parts by weight, and the pharmaceutical composition has the property that in a dissolved on pH 1, 2 buffered medium (SGFsp, Simulated Gastric Fluid sine pancreatin) in dissolved Form release in a concentration that after 2 hours at pH 1, 2 at least equal to the sixteen times the solubility value of the active ingredient alone at pH 1.2.
  • SGFsp Simulated Gastric Fluid sine pancreatin
  • Cationic, water-soluble (meth) acrylate copolymers are understood to mean those (meth) acrylate copolymers having cationic groups which are water-soluble at least over a certain pH range. As a rule, only one cationic, water-soluble (meth) acrylate copolymer is contained in the pharmaceutical composition. However, it is also possible if appropriate for two or more cationic, water-soluble (meth) acrylate copolymers to be present side by side or in a mixture.
  • the cationic, water-soluble (meth) acrylate copolymer may have the function of converting the poorly water-soluble active in the case of melt extrusion similar to US 6,391,338 to a state of higher solubility in the polymer blend.
  • Examples of preferred cationic, water-soluble (meth) acrylate copolymers are in particular (meth) acrylate copolymers having tertiary amino groups: Type EUDRAGIT® E
  • the cationic, water-soluble (meth) acrylate copolymer may be composed, in whole or in part, of alkyl acrylates and / or alkyl methacrylates having a tertiary amino group in the alkyl radical.
  • Suitable (meth) acrylate copolymers are known, for. From EP 0 058 765 B1.
  • the cationic, water-soluble (meth) acrylate copolymer may be composed of 30 to 80 wt .-% radically polymerized d- to C 4 -alkyl esters of acrylic or methacrylic acid and 70 to 20 wt .-% (meth) acrylate Compose monomers having a tertiary amino group in the alkyl radical.
  • Suitable monomers having tertiary amino functional groups are listed in US Pat. No. 4,705,695, column 3, line 64 to column 4, line 13. Particularly noteworthy are dimethylaminoethyl acrylate, 2-dimethylaminopropyl acrylate, dimethylaminopropyl methacrylate, dimethylaminobenzyl acrylate, dimethylaminobenzyl methacrylate, (3-dimethylamino-2,2-dimethly) propyl acrylate, dimethylamino-2,2-dimethly) propyl methacrylate, (3-diethylamino-2,2-dimethly) propyl acrylate and diethylamino-2,2-dimethly) propyl methacrylate. Particularly preferred is dimethylaminoethyl methacrylate.
  • the content of the monomers having tertiary amino groups in the copolymer can advantageously be between 20 and 70% by weight, preferably between 40 and 60% by weight.
  • the proportions of the C 1 to C 4 alkyl esters of acrylic or methacrylic acid is 70 to 30% by weight. Mention may be made of methyl methacrylate, ethyl methacrylate, butyl methacrylate, methyl acrylate, ethyl acrylate and butyl acrylate.
  • a suitable (meth) acrylate copolymer having tertiary amino groups may e.g. B. composed of 20-30% by weight of methyl methacrylate, 20-30% by weight of butyl methacrylate and 60-40% by weight of dimethylaminoethyl methacrylate.
  • a concretely suitable commercial (meth) acrylate copolymer having tertiary amino groups is e.g. B. from 25 wt .-% methyl methacrylate, 25 wt .-% butyl methacrylate and 50 wt .-% dimethylaminoethyl methacrylate constructed (EUDRAGIT® E100 or EUDRAGIT® E PO (powder form)).
  • EUDRAGIT® E100 or EUDRAGIT® E PO are soluble in water below about pH 5.0 and thus also soluble in the gastric juice.
  • Water-insoluble polymers are understood as meaning those polymers which are water-insoluble over the entire pH range from 1 to 14 or only swellable in water. As a rule, only one water-insoluble polymer is contained in the pharmaceutical composition. However, if appropriate, two or more water-insoluble polymers may also be present next to one another or in a mixture.
  • the water-insoluble polymer is believed to have the function of stabilizing the poorly water-soluble drug after release from the drug form for a prolonged period in the state of higher solubility, and thus to slow down or prevent solubilizing aggregation, recrystallization or precipitation.
  • water-insoluble polymers are in particular neutral (meth) acrylate copolymers and (meth) acrylate copolymers with quaternary ammonium groups: Neutral (meth) acrylate copolymers (type EUDRAGIT ® NE or type Eudragit® NM)
  • Neutral or essentially neutral methacrylate copolymers consist of at least 95, in particular at least 98, preferably at least 99, in particular at least 99, particularly preferably at 100% by weight of (meth) acrylate monomers having neutral radicals, in particular to C 4 - alkyl radicals.
  • Suitable (meth) acrylate monomers with neutral radicals are, for.
  • Preferred are methyl methacrylate, ethyl acrylate and methyl acrylate.
  • methacrylate monomers with anionic radicals eg.
  • acrylic acid and / or methacrylic acid e.g., acrylic acid and / or methacrylic acid.
  • EUDRAGIT® NE and Eudragit® NM are copolymers of 30% by weight of ethyl acrylate and 70% by weight of methyl methacrylate. Preference is given to neutral or substantially neutral methyl acrylate copolymers prepared according to WO 01/68767 as dispersions using 1-10% by weight of a nonionic emulsifier having an HLB value of from 15.2 to 17.3. The latter offer the advantage that a phase separation under formation of crystal structures by the emulsifier is omitted (Eudragit® NM).
  • EP 1 571 164 A2 corresponding, almost neutral (meth) acrylate copolymers, with small amounts, 0.05 to 1 wt .-% of monoolefinically unsaturated C3-C8 carboxylic acids but also by emulsion polymerization in the presence of comparatively small amounts of anionic emulsifiers, eg , B. 0.001 to 1 wt .-% are produced.
  • Suitable, water-insoluble (meth) acrylate copolymers are, for. B. from EP-A 181 515 or DE-PS 1 617 751 known. These are water-insoluble or water-only swellable polymers which are suitable for medicament coatings, regardless of the pH value.
  • the substance polymethylation in the presence of a radical-forming initiator dissolved in the monomer mixture should be mentioned.
  • the polymer can also be prepared by means of solution or precipitation polymerization. The polymer can be obtained in this way in the form of a fine powder, resulting in the Subtanzpolymerisation by milling, in solution and precipitation polymerization z. B. can be reached by spray drying.
  • a suitable water-insoluble (meth) acrylate copolymer is composed of 85 to 98% by weight of radically polymerized C 1 to C 4 alkyl esters of acrylic or methacrylic acid and 15 to 2% by weight of (meth) acrylate monomers with a quaternary amino group in the alkyl radical together.
  • Preferred C 1 to C 4 alkyl esters of acrylic or methacrylic acid are methyl acrylate, ethyl acrylate, butyl acrylate, butyl methacrylate and methyl methacrylate.
  • 2-trimethylammoniumethyl methacrylate chloride is particularly preferred.
  • a corresponding copolymer, for. B. from 50 to 70 wt .-% methyl methacrylate, 20 to 40 wt .-% ethyl acrylate and 7- 2 wt .-% 2-trimethylammoniumethyl methacrylate chloride.
  • a concretely suitable copolymer contains 65% by weight of methyl methacrylate, 30% by weight of ethyl acrylate and 5% by weight of 2-trimethylammoniumethyl methacrylate chloride (EUDRAGIT® RS).
  • Another suitable (meth) acrylate copolymer may, for. B. from 85 to less than 93 wt .-% C1 to C4 AI alkyl esters of acrylic or methacrylic acid and more than 7 to 15 wt .-% of (meth) acrylate monomers with a quaternary ammonium group in the alkyl be built.
  • Such (meth) acrylate monomers are commercially available and have long been used for retarding coatings.
  • a concrete suitable copolymer contains z. B.
  • mixtures of said (meth) acrylate copolymers are also suitable, in particular mixtures of EUDRAGIT® RS and EUDRAGIT® RL z. B. in the ratio of 9: 1 to 1: 9 parts by weight.
  • the pharmaceutical composition may also contain as water-insoluble polymer a polyvinyl acetate, a polyvinyl acetate copolymer (eg Kollicoat® SR 3OD or Kollidon® SR type), an ethylcellulose or a methylcellulose.
  • a polyvinyl acetate eg Kollicoat® SR 3OD or Kollidon® SR type
  • an ethylcellulose or a methylcellulose eg Kollicoat® SR 3OD or Kollidon® SR type
  • the or optionally the water-soluble (meth) acrylate copolymers and optionally the water-insoluble polymers in the pharmaceutical composition in a ratio of from 40 to 60 to 99 to 1, preferably in a ratio of 50 to 50 to 95 to 5, in particular in a ratio of 70 to 30 to 92 to 8 parts by weight.
  • a ratio of from 40 to 60 to 99 to 1 preferably in a ratio of 50 to 50 to 95 to 5, in particular in a ratio of 70 to 30 to 92 to 8 parts by weight.
  • the proportion of water-insoluble polymer, based on the active substance with a solubility in demineralized water of 3.3 g / l or less, should not be too high, since otherwise the desired solubility improvement after 120 min at pH 1, 2 at least 16- is not reached.
  • the water-insoluble polymer and the active ingredient should in a ratio of at most 3.5 parts by weight of water-insoluble polymer to 1 part by weight of active ingredient, preferably from at most 3.5 to 1 to 0.25 to 1 parts by weight, in particular from at most 2.5 to 1 to 0, 25 to 1 parts by weight.
  • the proportions each refer to their sum.
  • the pharmaceutical composition contains at least one, usually only one, but optionally also combinations of two or more active ingredients.
  • the active substance contained can therefore consist of a single or optionally also of several individual active substances.
  • the active ingredient or agents have a solubility in demineralized water of 3.3 g / l or less, preferably 2.2 g / l or less, in particular 1, 1 g / l or less.
  • the active ingredient or substances may, for. B. the group of BCS classes II and IV (Bio-Pharmaceutical Classification System according to Prof. Amidon, Amidon et al., Pharm. Res.12, 413-420 (1995)) and / or from the group of antiandrogens , Antidepressants, antidiabetics, antirheumatics, glucocorticoids, cytostatics, migraine agents, neuroleptics, antibiotics, estrogens, vitamins, psychopharmaca, ACE inhibitors, beta-blockers, ca-channel blockers, diuretics, Cardiac glycosides, antiepileptics, diuretics / antiglaucoma, uricostatic agents, H 2 - receptor blockers and antivirals.
  • BCS classes II and IV Bio-Pharmaceutical Classification System according to Prof. Amidon, Amidon et al., Pharm. Res.12, 413-420 (1995)
  • antiandrogens Antidepressants,
  • the BCS class II and IV agents have a solubility in demineralised water of 3.3 g / L or less.
  • the active ingredients of the BCS class II are well permeable, the BCS class IV poorly permeable.
  • the advantages according to the invention therefore develop, in particular, in the case of the active ingredients of BCS class II, since the availability of the active ingredient in solution represents the only limitation for its bioavailability.
  • BCS class IV drugs may also benefit from increased drug availability in solution to at least gradually achieve some improvement in bioavailability despite the limitation of poor cell uptake (permeability) of these drugs.
  • the invention relates to active substances having a solubility in demineralized water of 3.3 g / l or less, preferably 3.3 g / l or less, in particular 1.1 g / l or less.
  • solubility in water for the drug can according to DAB 10 (German Pharmacopoeia, 10th edition with 3rd supplement 1994, Deutscher maschinerverlag, Stuttgart and Govi Verlag, Frankfurt am Main, 2nd Amendment (1993), IV General Regulations, p 5 - 6, "Solubility and Solvents", sa Ph. Eur. 4.07, 2004).
  • SGFsp pH 1, 2 buffered medium
  • the values of the active ingredient formulated according to the invention and the non-formulated active substance are compared after 120 minutes. This simulates the conditions of average gastric transit time. In this comparison, the solubility of the active compound formulated according to the invention should be increased by at least 16 times, preferably by at least 18 times, in particular by at least 20 times.
  • the invention further relates to a
  • the organic solvent may also be a solvent mixture with other organic solvents and / or water. If water is contained, the proportion may only be so high that still all components, the two types of polymer and the active ingredient, in pass over a solution.
  • Suitable solvents are, for. As acetone, isopropanol or ethanol or mixtures thereof. Suitable is z. B is a mixture of isopropanol / acetone with 6 to 4 parts by weight. Suitable are also z. As ethanol / water mixtures, preferably with not more than 50 wt .-% water.
  • the process takes advantage of the fact that the active ingredient is poorly soluble in water and therefore can be solved comparatively well in an organic solvent.
  • the cationic, water-soluble (meth) acrylate copolymers are at the same time also soluble in an organic solvent.
  • the polymers of type EUDRAGIT® E also in the form of organic solutions with 12.5% solids content.
  • the water-insoluble polymer in turn, is readily soluble in an organic solvent. It is therefore possible to prepare a solution of all three components, wherein the active ingredient preserves the dissolved state even after removal of the solvent in the solid.
  • the level of the water-insoluble polymer in the mixture causes, for unknown reasons, that the original existing solubility of the active substance after release in a intestinal juice-like medium at pH 7.2 does not fall below the threshold value which after 4 hours is at least twice the solubility value of the active substance in corresponds to demineralized water, falls off.
  • the solvent method has the advantage of being easy to implement. "Melt extrusion"
  • melt extrusion process is preferred, i.a. because of the labor, health and environmental reasons problematic handling of solvents is eliminated.
  • the invention relates to a
  • the melt-extrusion process can be carried out with the aid of an extruder, in particular by means of a twin-screw extruder. It is advantageous if the extruder or the twin-screw extruder is equipped with a degassing zone.
  • the cationic, water-soluble and water-insoluble polymer can be incorporated as a solid, as a polymer solution or as a polymer dispersion.
  • the addition of the active ingredient can be carried out as a solid, as a solution or as a suspension.
  • the extrudate is preferably rounded out by means of strand granulation and hot cutting to cylindrical, elongated strand granules or by hot cutting with cooling Processed pellets.
  • EP 1 563 987 A1 describes a suitable device for producing rounded pellets (pelletizers).
  • Granules may preferably be added to powders with, e.g. B. with particle sizes of less than or equal to 1mm, preferably in the range of 50 to 500 microns, be ground.
  • the invention further relates to a
  • a process for producing a dosage form according to the invention comprising a pharmaceutical composition according to the invention, which comprises preparing a pharmaceutical composition by the solvent process or the melt extrusion process described above, further processed into granules, pellets or powders and optionally formulated by means of pharmaceutically customary excipients and known per se Way, z. B. by mixing, pressing, powder layering and / or encapsulation into a dosage form, for. B. to tablets, or preferably to a multiparticulate dosage form, in particular pellet-containing tablets, minitablets, capsules, sachets or dry juices processed.
  • the pharmaceutical composition of the invention is particularly suitable for the preparation of dosage forms in tablet form and for use in multiparticulate dosage forms.
  • the pharmaceutical composition according to the invention is preferably in the form of a powder and can be used directly in virtually all known pharmaceutical formulations in which the active ingredient is incorporated in powder form, instead of the active ingredient. In this way, for.
  • neutral cores (non-pareilles) in the powder layering process are coated with the pharmaceutical composition in powder form and a binder. Subsequently, the coated cores are formulated with other excipients and polymer layers, as specified in WO 01/68058 or WO 2005/046649, into ready-made dosage forms.
  • the pharmaceutical composition can be processed in the form of a powder without neutral core with binders by rounding, pressing into active ingredient-containing particles or pellets, which in turn can be provided with appropriate polymeric coating layers to control the drug delivery.
  • the production of multiparticulate dosage forms to tablets by compressing a pharmaceutically conventional binder with active ingredient-containing particles is z. Beckert et al. (1996), "Compression of enteric-coated pellets to disintegrating tablets", International Journal of Pharmaceutics 143, pp. 13-23, and described in detail in WO 96/01624.
  • Film coatings on active ingredient-containing pellets are usually applied in fluidized bed apparatus.
  • Film formers are usually mixed with plasticizers and release agents by a suitable method.
  • the film formers may be present as a solution or suspension.
  • the auxiliaries for film formation may also be dissolved or suspended.
  • Organic or aqueous solvents or dispersants may be used.
  • To stabilize the dispersion may additionally stabilizers be used (example: Tween 80 or other suitable emulsifiers or stabilizers).
  • release agents are glycerol monostearate or other suitable fatty acid derivatives, silicic acid derivatives or talc.
  • plasticizers are propylene glycol, phthalates, polyethylene glycols, sebacates or citrates, as well as other substances mentioned in the literature.
  • a separating layer may be applied between the active substance-containing and an optionally present enterosoluble copolymer layer which serves to separate the active ingredient and the coating material for the purpose of preventing interactions.
  • This layer may be made from inert film formers (e.g., HPMC or HPC) or e.g. Talc or other suitable pharmaceutical substances. Likewise, combinations of film formers and talcum or similar substances can be used.
  • a release layer of partially or fully neutralized copolymer dispersions e.g. anionic (meth) acrylate may contain.
  • Mixtures for the production of coated particle tablets are prepared by mixing the pellets with suitable binders for tabletting, if necessary adding disintegrants and, if necessary, adding lubricants.
  • the mixing can take place in suitable machines. Unsuitable are mixers that cause damage to the coated particles, eg. B. plowshare mixer. To achieve suitable short disintegration times, a special order of addition of the excipients to the coated particles may be required.
  • By premixing with the coated particles with the lubricating or Mold release agent Magnesium stearate can be hydrophobized its surface and thus sticking can be avoided.
  • suitable mixtures usually contain 3 to 15% by weight of a disintegrating agent, for. B. Kollidon CL and z. B. 0.1 to 1 wt .-% of a lubricant and mold release agent such as magnesium stearate.
  • a disintegrating agent for. B. Kollidon CL and z. B. 0.1 to 1 wt .-% of a lubricant and mold release agent such as magnesium stearate.
  • the binder content is determined by the required proportion of coated particles.
  • Typical binders are z. As Cellactose ® , microcrystalline cellulose, calcium phosphates, Ludipress ® , lactose or other suitable sugars, calcium sulfates or starch derivatives. Preference is given to substances having a low bulk density.
  • disintegrants are crosslinked starch or cellulose derivatives, as well as crosslinked polyvinylpyrrolidone. Likewise, cellulose derivatives are suitable. By selecting a suitable binder, the use of disintegrant can be omitted.
  • Typical lubricants and mold release agents are magnesium stearates or other suitable salts of fatty acids or substances listed in the literature for this purpose (e.g., lauric acid, calcium stearate, talc, etc.).
  • suitable machinery e.g., tablet press with external lubrication
  • suitable formulations the use of a lubricant and mold release agent in the blend may be eliminated.
  • the mixture may optionally be accompanied by a flow improver (eg highly disperse silicic acid derivatives, talc, etc.).
  • a flow improver eg highly disperse silicic acid derivatives, talc, etc.
  • the tableting can be carried out on conventional tablet presses, eccentric or rotary tablet presses, at pressing forces in the range of 5 to 40 kN, preferably 10 to 20 kN.
  • the tablet presses can be equipped with systems for external lubrication.
  • auxiliaries or additives are preferably added to the composition according to the invention in a manner known per se.
  • all adjuvants used must be toxicologically safe and in particular be used in medicaments without risk for patients.
  • Amounts used and the usual additives in drug coatings or coatings are familiar to the expert.
  • Usual additives can z.
  • Release agents usually have lipophilic properties and are usually added to the spray suspensions. They prevent agglomeration of the cores during the filming. Preference is given to talc, Mg or Ca Stearate, ground silicic acid, kaolin or nonionic emulsifiers having an HLB value between 3 and 8. Usual amounts of release agent used are between 0.5 to 100 wt .-% based on the sum of active ingredient, water-soluble (meth) acrylate copolymer and water-insoluble polymer.
  • the pigments to be used are non-toxic and suitable for pharmaceutical purposes. See z. Also: German Research Foundation, Dyestuffs for Food, Harald Boldt Verlag KG, Boppard (1978); German Food Review 74, No. 4, p. 156 (1978); Pharmaceutical Dye Ordinance AmFarbV of 25.08.1980. Geeigente pigments are z.
  • yellow orange S E110, Cl 15985,
  • E numbers of the pigments refer to an EU numbering. See also "Deutsche Klastician, Dyestuffs for Food, Harald Boldt Verlag KG, Boppard (1978); German Food Review 74, No. 4, p. 156 (1978); Pharmaceutical Dye Ordinance AmFarbV of 25.08.1980.
  • the FD & C numbers refer to the approval in Food, Drugs and Cosmetics US Food and Drug Administration (FDA): US Food and Drug Administration, Center for Food Safety and Applied Nutrition, Code of Federal Regulations - Title 21 Color Additive Regulations Part 82, Listing of Certified Provisionally Listed Colors and Specifications (CFR 21 Part 82).
  • additives may also be plasticizers. Usual amounts are between 0 and 50, preferably 5 to 20 wt .-%.
  • plasticizers can influence the functionality of the polymer layer. Plasticizers achieve by physical interaction with the polymer, a lowering of the glass transition temperature and promote, depending on the amount added to the film. Suitable substances generally have a molecular weight between 100 and 20,000 and contain one or more hydrophilic groups in the molecule, eg. B. hydroxyl, ester or amino groups.
  • plasticizers examples include citric acid alkyl esters, glycerol esters, alkyl phthalates, sebacic acid alkyl esters, sucrose esters, sorbitan esters, diethyl sebacate, dibutyl sebacate and polyethylene glycols 200 to 12,000.
  • Preferred plasticizers are triethyl citrate (TEC), acetyl triethyl citrate (ATEC) and dibutyl sebacate (DBS).
  • TEC triethyl citrate
  • ATC acetyl triethyl citrate
  • DBS dibutyl sebacate
  • Citric acid and sebacic acid esters are preferably used.
  • plasticizer to the formulation can in a known manner, directly, in aqueous solution or after thermal pretreatment of a Mixture be made. Also, mixtures of plasticizers can be used.
  • the invention further relates to a dosage form containing a pharmaceutical composition according to the invention.
  • the invention further relates to the use of the pharmaceutical composition according to the invention for the preparation of a dosage form.
  • the pharmaceutical composition may preferably be incorporated in powder form instead of a powdery active ingredient.
  • the powder has the property of releasing the active substance contained in a medium buffered to pH 1.2 in a concentration which, after 2 hours at pH 1.2, is at least 16 times the solubility value of the active ingredient alone at pH 1, 2 corresponds. This makes it possible to incorporate poorly soluble active ingredients in a state of increased solubility in drug forms of all kinds.
  • An advantageous effect of the pharmaceutical composition according to the invention consists in particular in that poorly soluble active ingredients are converted into a state of higher solubility in water, this state, in contrast to the prior art (see Example 1), over a period of 120 min at pH 1, 2 is maintained stable.
  • the period of 120 min at pH 1, 2 simulates an average gastric transit time. In this way it is possible, after initially increased solubility of the active ingredient, to reduce or even prevent its recrystallization in the course of the stomach residence time. This significantly increases the bioavailability in terms of time and in particular at the moment of the transition in the intestinal tract.
  • the gastric juice-like environment represents a high test requirement, so that it can be assumed that the state of increased solubility, if it is reached stably in the test at pH 1, 2 after 120 min, even after passing into the intestine section at the prevailing there higher pH values are no longer significantly adversely affected.
  • the pharmaceutical composition according to the invention is therefore suitable not only for active ingredients that are to be released in the stomach, but practically also for all other dosage forms, eg. B. for enteric-coated and / or retarding formulated drug forms that release the drug only in the intestine.
  • all other dosage forms eg. B. for enteric-coated and / or retarding formulated drug forms that release the drug only in the intestine.
  • the pharmaceutical composition is preferably in powder form and can be used in its place in virtually any formulation in which the active ingredient is processed in powder form. Due to the increased solubility, fundamentally new therapeutic options are opened in this way.
  • EUDRAGIT® E is a water-soluble copolymer of 25% by weight of methyl methacrylate, 25% by weight of butyl methacrylate and 50% by weight of dimethylaminoethyl methacrylate
  • EUDRAGIT® NE is a water-insoluble copolymer of 30% by weight of ethyl acrylate and 70% by weight of methyl methacrylate.
  • EUDRAGIT® RL is a water-insoluble copolymer of 60% by weight of methyl methacrylate, 30% by weight of ethyl acrylate and 10% by weight of 2-trimethylammonium ethyl methacrylate chloride.
  • Kollicoat® SR is a water-insoluble polymer (a polyvinyl acetate copolymer)
  • Kollicoat® IR (a vinyl acetate-ethylene glycol block copolymer) is a water-soluble polymer
  • PEG 6000 Polyethylene glycol 6000 (water-soluble polymer) B) Preparation of the extrudates for Examples 1 to 14
  • the samples are produced by melt extrusion on a twin-screw extruder (Leistritz MICRO 18 GL 40 D Pharma).
  • the temperature was chosen so that at least one zone is above the melting point of the active ingredient.
  • the extrusion was carried out in a range between 70-170 0 C.
  • Felodipine the water-soluble (meth) acrylate copolymer EUDRAGIT® E and optionally the "second" polymer are metered in via solid or liquid feeders, mixed in an extruder, melted and extruded Ratio to the active ingredient of at most 3.5 to 1 before. The speed was 200-250 rpm. The melt obtained is drawn off via an air-cooled draw-off belt and then comminuted in a strand granulator. Subsequently, the granules are ground in a Retsch Ultra centrifugal mill with a 250 ⁇ m sieve insert at 6000 1 / min and then sieved ( ⁇ 250 ⁇ m).
  • composition of the individual extrudates in% by weight
  • the release of the active ingredient from the ground granules was carried out in a paddle apparatus (DT 700 dissolution tester, Erweka) USP 26 method 2.
  • the samples were weighed in each case corresponding to 10 mg of Felodipine.
  • 500ml SGFsp simulated gastric fluid sine pancreatin, USP
  • pH 1, 2 37 ° C ⁇ 0.5
  • the stirring speed was 100 rpm.
  • 5 ml samples were withdrawn at regular intervals through a membrane filter (Rezist® 30 / 0.45 ⁇ m PTFE, Schleicher & Schull) and diluted with methanol 1: 1. The first 2 ml were discarded. The removed volume was replaced with fresh, tempered medium.
  • Felodipine has a solubility in water ⁇ 1 mg / l (0.0001 g / l).
  • the solubility for felodipine was determined for comparison in pH 1, 2 buffered medium (SGFsp pH 1, 2).
  • SGFsp pH 1, 2 pH 1, 2 buffered medium
  • 10 mg in 20 ml of medium were kept in motion for 24 hours on an orbital shaker at 37 ° C.
  • the concentration was determined by means of HPLC.
  • Example 1 (not according to the invention):
  • Example 1 Without the inventive addition of a water-insoluble polymer, the initially good solubility (after 5 minutes, see the individual values of Example 1) falls to the factor 7.4 after 120 minutes.
  • Examples 11 to 14 If a water-soluble polymer is used instead of a water-insoluble polymer, the solubility improvement is less than 16 times the active ingredient alone.

Abstract

L'invention concerne une composition pharmaceutique contenant un mélange d'au moins un copolymère de (méth)acrylate cationique, soluble dans l'eau, d'au moins un polymère insoluble dans l'eau, et d'au moins un agent actif présentant une solubilité dans l'eau déminéralisée de 3,3 g/l ou moins. La composition selon l'invention est caractérisée en ce que le polymère insoluble dans l'eau et l'agent actif sont présents dans un rapport de max. 3,5 sur 1 parts en poids, et en ce que ladite composition présente la propriété de libérer l'agent actif qu'elle contient dans un milieu tamponné à un pH de 1,2 sous forme dissoute, dans une concentration correspondant au moins à 16 fois l'indice de solubilité de l'agent actif seul à un pH de 1,2, après 2 heures à un pH de 1,2.
PCT/EP2007/050465 2006-02-03 2007-01-17 Compositions pharmaceutiques contenant des mélanges de polymères et d'agents actifs peu solubles dans l'eau WO2007090721A1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
PL07703962T PL1978936T3 (pl) 2006-02-03 2007-01-17 Kompozycje farmaceutyczne zawierające mieszaniny polimerów i trudno rozpuszczalnych w wodzie substancji czynnych
US12/159,538 US20090011007A1 (en) 2006-02-03 2007-01-17 Pharmaceutical Compositions Containing Mixtures of Polymers and Active Agents Poorly Soluble in Water
EP07703962.6A EP1978936B1 (fr) 2006-02-03 2007-01-17 Compositions pharmaceutiques contenant des mélanges de polymères et d'agents actifs peu solubles dans l'eau
BRPI0707465A BRPI0707465B8 (pt) 2006-02-03 2007-01-17 composições farmacêuticas compreendendo misturas de polímeros e ingredientes ativos dificilmente solúveis em água, seu uso e seus processos de preparação, forma farmacêutica e seu processo de produção
ES07703962T ES2427724T3 (es) 2006-02-03 2007-01-17 Composiciones farmacéuticas, que contienen mezclas de polímeros y de sustancias activas difícilmente solubles en agua
KR1020087019038A KR101387249B1 (ko) 2006-02-03 2007-01-17 물에 난용성인 유효 성분과 중합체의 혼합물을 함유하는제약 조성물
CA2641351A CA2641351C (fr) 2006-02-03 2007-01-17 Compositions pharmaceutiques contenant des melanges de polymeres et d'agents actifs peu solubles dans l'eau
SI200731314T SI1978936T1 (sl) 2006-02-03 2007-01-17 Farmacevtski sestavki, ki vsebujejo mešanice polimerov in v vodi slabo topna aktivna sredstva
JP2008552772A JP2009525300A (ja) 2006-02-03 2007-01-17 水難溶性のポリマー及び活性薬剤の混合物を含む医薬組成物
IL191604A IL191604A (en) 2006-02-03 2008-05-21 Delayed-release pharmaceutical preparations containing polymers and poorly dissolved water-active ingredients and process for preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006005485 2006-02-03
DE102006005485.7 2006-02-03

Publications (1)

Publication Number Publication Date
WO2007090721A1 true WO2007090721A1 (fr) 2007-08-16

Family

ID=38229086

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/050465 WO2007090721A1 (fr) 2006-02-03 2007-01-17 Compositions pharmaceutiques contenant des mélanges de polymères et d'agents actifs peu solubles dans l'eau

Country Status (13)

Country Link
US (1) US20090011007A1 (fr)
EP (1) EP1978936B1 (fr)
JP (1) JP2009525300A (fr)
KR (1) KR101387249B1 (fr)
CN (1) CN101370480A (fr)
BR (1) BRPI0707465B8 (fr)
CA (1) CA2641351C (fr)
ES (1) ES2427724T3 (fr)
IL (1) IL191604A (fr)
PL (1) PL1978936T3 (fr)
SI (1) SI1978936T1 (fr)
TW (1) TWI394584B (fr)
WO (1) WO2007090721A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008017867A2 (fr) * 2006-08-10 2008-02-14 Cipla Limited Composition orale solide antirétrovirale
EP1909762A2 (fr) * 2005-07-28 2008-04-16 Isp Investments Inc. Efavirenz amorphe et methode de production
WO2008133537A1 (fr) * 2007-04-27 2008-11-06 Zaklady Farmaceutyczne Polpharma Sa Composition pharmaceutique à stabilité améliorée comprenant un inhibiteur de l'ace ou un de ses sels pharmacocompatibles, et leurs méthodes de fabrication

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100297248A1 (en) * 2004-09-01 2010-11-25 Board Of Regents, The University Of Texas System Encapsulated particles for amorphous stability enhancement
US20060045822A1 (en) * 2004-09-01 2006-03-02 Board Of Regents, The University Of Texas System Plasma polymerization for encapsulating particles
GB0607105D0 (en) * 2006-04-10 2006-05-17 Leuven K U Res & Dev Enhancing solubility and dissolution rate of poorly soluble drugs
US8088451B2 (en) 2008-03-13 2012-01-03 Board Of Regents, The University Of Texas System Covalently functionalized particles for synthesis of new composite materials
WO2011146078A1 (fr) * 2010-05-21 2011-11-24 Board Of Regents, The University Of Texas System Particules encapsulées pour une libération entérique
PL2654731T3 (pl) * 2010-12-23 2017-01-31 AbbVie Deutschland GmbH & Co. KG Formulacje stałe o opóźnionym uwalnianiu na podstawie dyspersji stałych
EP2550863A1 (fr) * 2011-07-27 2013-01-30 Bayer Intellectual Property GmbH Particules contenant une matière active à base de polyacrylate
US20150011525A1 (en) * 2011-09-13 2015-01-08 Isp Investments Inc. Solid dispersion of poorly soluble compounds comprising crospovidone and at least one water-soluble polymer
PL2833880T3 (pl) * 2012-04-02 2018-03-30 Pharma Seeds Create, Llc Stała doustna kompozycja dawkowana ibuprofenu zawierająca kopolimer kwasu metakrylowego
KR101659983B1 (ko) * 2012-12-31 2016-09-26 주식회사 삼양바이오팜 용융 압출된 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
JP6052319B2 (ja) 2015-03-25 2016-12-27 Ｎｔｔエレクトロニクス株式会社 動画像符号化装置
US10414241B2 (en) 2016-06-30 2019-09-17 Emerson Climate Technologies, Inc. Systems and methods for capacity modulation through eutectic plates
US10315495B2 (en) 2016-06-30 2019-06-11 Emerson Climate Technologies, Inc. System and method of controlling compressor, evaporator fan, and condenser fan speeds during a battery mode of a refrigeration system for a container of a vehicle
US10532632B2 (en) 2016-06-30 2020-01-14 Emerson Climate Technologies, Inc. Startup control systems and methods for high ambient conditions
US10569620B2 (en) 2016-06-30 2020-02-25 Emerson Climate Technologies, Inc. Startup control systems and methods to reduce flooded startup conditions
US10828963B2 (en) 2016-06-30 2020-11-10 Emerson Climate Technologies, Inc. System and method of mode-based compressor speed control for refrigerated vehicle compartment
US10300766B2 (en) * 2016-06-30 2019-05-28 Emerson Climate Technologies, Inc. System and method of controlling passage of refrigerant through eutectic plates and an evaporator of a refrigeration system for a container of a vehicle
US10328771B2 (en) 2016-06-30 2019-06-25 Emerson Climated Technologies, Inc. System and method of controlling an oil return cycle for a refrigerated container of a vehicle
US10562377B2 (en) 2016-06-30 2020-02-18 Emerson Climate Technologies, Inc. Battery life prediction and monitoring
CN111971026A (zh) 2018-05-24 2020-11-20 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件
EP3801378A4 (fr) 2018-05-24 2022-02-23 Celanese EVA Performance Polymers LLC Dispositif implantable pour la libération prolongée d'un composé médicamenteux macromoléculaire
CN110755396B (zh) * 2019-12-06 2022-04-08 北京悦康科创医药科技股份有限公司 一种布洛芬缓释小丸及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0142877A2 (fr) * 1983-10-24 1985-05-29 "PHARLYSE", Société Anonyme Comprimés pharmaceutiques à libération prolongée, leur préparation et leur utilisation
EP0682945A2 (fr) * 1994-05-18 1995-11-22 Lannacher Heilmittel Ges.m.b.H. Préparation orale à effet retard
EP1064935A1 (fr) * 1999-06-28 2001-01-03 Adir Et Compagnie Composition pharmaceutique solide thermoformable à libération côntrolée
US6391338B1 (en) * 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
WO2003000225A2 (fr) * 2001-06-21 2003-01-03 Aventis Pharma S.A. Formulation pharmaceutique au gout masque et son procede de preparation
US20040071773A1 (en) * 2000-06-30 2004-04-15 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2068402C (fr) * 1991-06-14 1998-09-22 Michael R. Hoy Enrobage pour masquer le gout pouvant etre utilise dans des comprimes pharmaceutiques croquables
US20030064108A1 (en) * 1996-04-23 2003-04-03 Stefan Lukas Taste masked pharmaceutical compositions
AU6228799A (en) * 1998-10-26 2000-05-15 Tanabe Seiyaku Co., Ltd. Sustained-release particles
WO2004009059A1 (fr) * 2002-07-19 2004-01-29 Aventis Pharma S.A. Composition orale de telithromycine possedant un gout agreable
DE10304403A1 (de) * 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
EP1734953A4 (fr) * 2004-03-02 2008-08-20 Abeille Pharmaceuticals Inc Co-pr parations de kits d'agents bioacitfs

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0142877A2 (fr) * 1983-10-24 1985-05-29 "PHARLYSE", Société Anonyme Comprimés pharmaceutiques à libération prolongée, leur préparation et leur utilisation
EP0682945A2 (fr) * 1994-05-18 1995-11-22 Lannacher Heilmittel Ges.m.b.H. Préparation orale à effet retard
US6391338B1 (en) * 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
EP1064935A1 (fr) * 1999-06-28 2001-01-03 Adir Et Compagnie Composition pharmaceutique solide thermoformable à libération côntrolée
US20040071773A1 (en) * 2000-06-30 2004-04-15 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
WO2003000225A2 (fr) * 2001-06-21 2003-01-03 Aventis Pharma S.A. Formulation pharmaceutique au gout masque et son procede de preparation

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909762A2 (fr) * 2005-07-28 2008-04-16 Isp Investments Inc. Efavirenz amorphe et methode de production
WO2008017867A2 (fr) * 2006-08-10 2008-02-14 Cipla Limited Composition orale solide antirétrovirale
WO2008017867A3 (fr) * 2006-08-10 2009-04-16 Cipla Ltd Composition orale solide antirétrovirale
WO2008133537A1 (fr) * 2007-04-27 2008-11-06 Zaklady Farmaceutyczne Polpharma Sa Composition pharmaceutique à stabilité améliorée comprenant un inhibiteur de l'ace ou un de ses sels pharmacocompatibles, et leurs méthodes de fabrication

Also Published As

Publication number Publication date
EP1978936A1 (fr) 2008-10-15
CN101370480A (zh) 2009-02-18
PL1978936T3 (pl) 2013-11-29
TWI394584B (zh) 2013-05-01
BRPI0707465B1 (pt) 2020-01-14
EP1978936B1 (fr) 2013-07-10
KR20080090494A (ko) 2008-10-08
IL191604A0 (en) 2008-12-29
BRPI0707465B8 (pt) 2022-07-05
CA2641351C (fr) 2014-05-06
TW200808357A (en) 2008-02-16
CA2641351A1 (fr) 2007-08-16
JP2009525300A (ja) 2009-07-09
ES2427724T3 (es) 2013-10-31
US20090011007A1 (en) 2009-01-08
IL191604A (en) 2013-05-30
KR101387249B1 (ko) 2014-05-21
BRPI0707465A2 (pt) 2011-05-03
SI1978936T1 (sl) 2013-10-30

Similar Documents

Publication Publication Date Title
EP1978936B1 (fr) Compositions pharmaceutiques contenant des mélanges de polymères et d'agents actifs peu solubles dans l'eau
EP1478352B1 (fr) Forme pharmaceutique et procédé de fabrication
EP1771157B1 (fr) Forme galenique multiparticulaire pour principes actifs faiblement solubles, et procede de production de la forme galenique
EP2429492B1 (fr) Préparations pharmaceutiques solides contenant des copolymères à base de polyéthers en association avec des polymères peu solubles dans l'eau
EP2120955A1 (fr) Granules pourvus d'une matrice comportant une substance active et d'un enrobage polymère, et procédé de production de ces granules
EP1848751B1 (fr) Copolymere de (meth)acrylate anionique partiellement neutralise
DE102005032806A1 (de) Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
EP0925060A1 (fr) Pastilles se decomposant rapidement
WO2006072367A1 (fr) Produits pharmaceutiques solides, administres par voie orale et contenant du rivaroxaban, a liberation modifiee
DE10319458A1 (de) Arzneiform und Verfahren zu ihrer Herstellung
EP1113787A1 (fr) Preparations pharmaceutiques a liberation controlee en fonction de l'agitation et leur procede de production
EP1478344B1 (fr) Extrusion de fusion de sels d'agents actifs
EP2349218B1 (fr) Procédé de fabrication de formes posologiques orales à libération contrôlée
EP2463327A2 (fr) Procédé de fabrication de granulés comprenant au moins un composant soluble dans l'eau
EP1487422B1 (fr) Films de revetement a liberation tres controlee et a grande stabilite
WO2013045352A1 (fr) Procédé de fabrication d'agents de pelliculage solides contenant des pigments, sous forme de granulés à base d'agents filmogènes gastrorésistants pour l'enrobage de formes galéniques
MX2008008915A (es) Composiciones farmaceuticas que comprenden mezclas de polimeros e ingredientes activos moderadamente solubles en agua

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007703962

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 191604

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12159538

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/008915

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 200780003053.7

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2641351

Country of ref document: CA

Ref document number: 4048/CHENP/2008

Country of ref document: IN

Ref document number: 1020087019038

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2008552772

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: PI0707465

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080804